CD19-targeted chimeric antigen receptor T cells eliminate both malignant and normal B cells. Targeting immunoglobulin light chains instead of CD19 could preserve half of the normal B cells and provide an alternative target.

See related article by Ranganathan et al., p. 5951

©2021 American Association for Cancer Research
2021
American Association for Cancer Research
You do not currently have access to this content.